Bio

Dr. Wu completed her medical degree and a Ph.D. in clinical medicine from West China Medical College. Following this, she underwent postdoctoral training at the Smidt Heart Institute of Cedars-Sinai Medical Center, where her research centered on endovascular inflammation, calcium regulation in HFpEF (Heart Failure with Preserved Ejection Fraction), and the potential of Cardiosphere-derived cells (CDCs) and their exosomes (CDCexo) in heart failure treatment. Building on her proficiency in calcium handling and cardiosphere-derived cell-based therapies in rodent models, Dr. Wu became a part of the Stanford Cardiovascular Institute. Here, she delved deeper into regenerative medicine solutions for cardiovascular ailments. Currently, Dr. Wu spearheads research on transthyretin cardiac amyloidosis (ATTR), a rare and devastating protein misfolding disease. Utilizing iPSC, animal models, and human samples, her pioneering work promises significant insights into this life-threatening condition, aiming to enhance patient outcomes.

Professional Education

  • M.D./Ph.D., Sichuan University, West China School of Medicine, Clinical Medicine (2018)

Stanford Advisors

Additional Info

All Publications

  • Rapid 3D bioprinting of a multicellular model recapitulating pterygium microenvironment BIOMATERIALS Zhong, Z., Wang, J., Tian, J., Deng, X., Balayan, A., Sun, Y., Xiang, Y., Guan, J., Schimelman, J., Hwang, H., You, S., Wu, X., Ma, C., Shi, X., Yao, E., Deng, S. X., Chen, S. 2022; 282: 121391

    Abstract

    Pterygium is an ocular surface disorder with high prevalence that can lead to vision impairment. As a pathological outgrowth of conjunctiva, pterygium involves neovascularization and chronic inflammation. Here, we developed a 3D multicellular in vitro pterygium model using a digital light processing (DLP)-based 3D bioprinting platform with human conjunctival stem cells (hCjSCs). A novel feeder-free culture system was adopted and efficiently expanded the primary hCjSCs with homogeneity, stemness and differentiation potency. The DLP-based 3D bioprinting method was able to fabricate hydrogel scaffolds that support the viability and biological integrity of the encapsulated hCjSCs. The bioprinted 3D pterygium model consisted of hCjSCs, immune cells, and vascular cells to recapitulate the disease microenvironment. Transcriptomic analysis using RNA sequencing (RNA-seq) identified a distinct profile correlated to inflammation response, angiogenesis, and epithelial mesenchymal transition in the bioprinted 3D pterygium model. In addition, the pterygium signatures and disease relevance of the bioprinted model were validated with the public RNA-seq data from patient-derived pterygium tissues. By integrating the stem cell technology with 3D bioprinting, this is the first reported 3D in vitro disease model for pterygium that can be utilized for future studies towards personalized medicine and drug screening.

    View details for DOI 10.1016/j.biomaterials.2022.121391

    View details for Web of Science ID 000788717500002

    View details for PubMedID 35101743

https://orcid.org/0000-0003-1020-6232